How many institutional investors hold URGN?

3 tracked institutional investors disclosed a position in URGN (UROGEN PHARMA LTD) in their most recent 13F filing.

Who is the largest institutional holder of URGN?

Ken Griffin, Citadel Advisors, holds the largest disclosed position in URGN, valued at $19M.

Where does this URGN ownership data come from?

SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.

URGN — UROGEN PHARMA LTD

Name: UROGEN PHARMA LTD (URGN) — Institutional Ownership
Creator: InvestorLens
License: https://www.sec.gov/about/website-policies

Public company

For educational research only.InvestorLens analyzes public regulatory filings (SEC EDGAR, STOCK Act PTRs) that may be delayed by 45 days or more. Information shown is historical and is not financial, legal, or tax advice, nor a recommendation or solicitation to buy or sell any security. Always do your own research.

InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.

Sourced from SEC EDGAR public filings

About UROGEN PHARMA LTD (URGN)

UROGEN PHARMA LTD (URGN) appears in the most recent 13F filings of 3 tracked institutional investors. The largest disclosed position is held by Ken Griffin (Citadel Advisors), valued at $19M. Across recent filings, tracked investors recorded 1 new positions, 0 increased, 2 reduced, and 0 exited. All data sourced from SEC 13F filings.

Smart Money Consensus™

Based on recent institutional activity in URGN

/100

Institutional Distribution

Added / Increased1

Reduced2

Exited0

BearishBullish

Crowded Trade Score™

How many top investors track URGN

/100

Emerging Interest

3investors

A small number of top investors own this.

UndiscoveredCrowded

151015+

URGN Ownership Composition

How UROGEN PHARMA LTD is held across tracked investor types, based on reported 13F positions.

Dominant Type

Other

86% of tracked value

Institutions

tracked investors

Total Reported

$14.4M

combined 13F value

Other85.6%
Growth Funds14.4%

Other(2)

85.6%

Growth Funds(1)

14.4%

Tracked investors reporting URGN

Investor	Firm	Shares	Market value	% of portfolio	As of
Ken Griffin	Citadel Advisors	316.2K	$5.7M	0.00%	Mar 31, 2026
Izzy Englander	Millennium Management	370.9K	$6.7M	0.00%	Mar 31, 2026
Cathie Wood	ARK Investment Management	115.5K	$2.1M	0.02%	Mar 31, 2026

Ken GriffinMar 31, 2026
Citadel Advisors
Shares
316.2K
Value
$5.7M
% Portfolio
0.00%
Izzy EnglanderMar 31, 2026
Millennium Management
Shares
370.9K
Value
$6.7M
% Portfolio
0.00%
Cathie WoodMar 31, 2026
ARK Investment Management
Shares
115.5K
Value
$2.1M
% Portfolio
0.02%

Recent activity

Investor	Action	Δ %	Current value	Filing date
Cathie Wood	Reduced	-4.89%	$2.1M	May 12, 2026
Cathie Wood	Reduced	-4.13%	$2.8M	Feb 11, 2026
Cathie Wood	New	—	$2.5M	Nov 12, 2025

Cathie Wood
Reduced
$2.1M(-4.89%)May 12, 2026
Cathie Wood
Reduced
$2.8M(-4.13%)Feb 11, 2026
Cathie Wood
New
$2.5MNov 12, 2025

Frequently asked questions

How many institutional investors hold URGN?: 3 tracked institutional investors disclosed a position in URGN (UROGEN PHARMA LTD) in their most recent 13F filing.
Who is the largest institutional holder of URGN?: Ken Griffin, Citadel Advisors, holds the largest disclosed position in URGN, valued at $19M.
Did institutional ownership of URGN increase or decrease?: Across recent 13F filings, tracked investors recorded 1 new positions, 0 increased, 2 reduced, and 0 fully exited URGN.
Where does this URGN ownership data come from?: SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.